• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Keros Therapeutics Inc.

    4/22/26 4:03:57 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KROS alert in real time by email
    DEFA14A 1 tm261345d3_defa14a.htm DEFA14A

     

     

     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement
       
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ¨ Definitive Proxy Statement
       
    x Definitive Additional Materials
       
    ¨ Soliciting Material Pursuant to § 240.14a-12

    Keros Therapeutics, Inc.

     

    (Name of Registrant as Specified In Its Charter)

     

     

     

    (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box)

     

    x No fee required.
       
    ¨ Fee paid previously with preliminary materials.
       
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
       
     

     

     

     

     

     

    GRAPHIC

    KEROS THERAPEUTICS, INC. Important Notice Regarding the Internet Availability of Proxy Materials for the Annual Meeting of Stockholders to be held virtually on June 3, 2026 at 11:00 A.M. ET. This communication is not a form of voting and presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Notice to Stockholders, Proxy Statement and Annual Report are available at http://web.viewproxy.com/Keros/2026 If you want to receive a paper or e -mail copy of these documents, you must request one by following the instructions below on or before May 26, 2026 to facilitate timely delivery. There is no charge to you for requesting a copy. Important information regarding the Internet availability of the Company’s proxy materials, instructions for accessing your proxy materials and voting online, and instructions for requesting paper or e -mail copies of your proxy materials are outlined in this Notice. You must use the 11 CONTROL NUMBER -digit Virtual Control Number located in the box to attend the Annual Meeting virtually, to vote via Internet, or to request proxy materials. STOCKHOLDERS ARE CORDIALLY INVITED TO ATTEND THE ANNUAL MEETING. To the Stockholders of Keros Therapeutics, Inc.: The 2026 Annual Meeting of Stockholders of Keros Therapeutics, Inc. will be held virtually on June 3, 2026 at 11:00 A.M. ET. As a Registered Holder, you may attend and vote your shares at the virtual Annual Meeting by registering at https://web.viewproxy.com/Keros/2026 and using the Virtual Control Number above. Your registration must be received by 11:59 P.M. ET on June 2, 2026. On the day of the Annual Meeting, if you have properly registered, you may log in using the link you received via e-mail in your registration confirmation and follow the instructions to vote your shares. Please have your Virtual Control Number with you during the Annual Meeting in order to vote. Further instructions on how to attend and vote during the Annual Meeting are contained in the Proxy Statement in the sections titled “Questions and Answers About These Proxy Materials and Voting – How do I attend the Annual Meeting?” and “Questions and Answers About These Proxy Materials and Voting – How can I vote?” The Board recommends a vote “FOR” all the nominees listed in Proposal 1, and “FOR” Proposals 2 and 3. 1. To elect the two (2) nominees for Class III director named below to hold office until the 2029 Annual Meeting of Stockholders. NOMINEES: (1) Jean-Jacques Bienaimé (2) Charles Newton 2. To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. 3. To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the accompanying Proxy Statement. NOTE: To conduct any other business properly brought before the meeting or any adjournment thereof.

    GRAPHIC

    The Securities and Exchange Commission rules permit us to make our proxy materials available to our stockholders via the Internet. Material for this Annual Meeting and future meetings may be requested by one of the following methods: E-Mail: By e -mail at: [email protected] * If requesting material by e -mail, please send a blank e -mail with the company name and your 11-digit Virtual Control Number in the subject line. No other requests, instructions, or other inquiries should be included within this e -mail request. Internet: Go to https://web.viewproxy.com/Keros/2026 Have the 11-digit Virtual Control Number available when you access the website and follow the instructions. Telephone: Call 1-877 -777 -2857 Toll Free CONTROL NUMBER VOTING METHODS Via Internet prior to the Annual Meeting: Go to www.FCRvote.com/KROS Have your 11-digit Virtual Control Number available and follow the prompts. • Your electronic vote prior to the Annual Meeting authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated, and returned a proxy card. Via Internet during the Annual Meeting: Go to www.FCRvote.com/KROS Have your 11-digit Virtual Control Number available and follow the prompts. KEROS THERAPEUTICS, INC.

    Get the next $KROS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KROS

    DatePrice TargetRatingAnalyst
    10/20/2025$26.00Overweight
    Wells Fargo
    6/10/2025$18.00Buy → Neutral
    BofA Securities
    1/21/2025Overweight → Neutral
    Cantor Fitzgerald
    1/17/2025$15.00Outperform → Neutral
    Wedbush
    12/16/2024$102.00 → $63.00Outperform
    Oppenheimer
    12/16/2024Buy → Neutral
    Guggenheim
    12/13/2024$100.00 → $47.00Buy
    H.C. Wainwright
    12/12/2024Buy → Hold
    TD Cowen
    More analyst ratings

    $KROS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Keros Therapeutics with a new price target

    Wells Fargo initiated coverage of Keros Therapeutics with a rating of Overweight and set a new price target of $26.00

    10/20/25 8:00:48 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Keros Therapeutics from Buy to Neutral and set a new price target of $18.00

    6/10/25 7:53:18 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Keros Therapeutics from Overweight to Neutral

    1/21/25 7:51:46 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS

    LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it has entered into an agreement with the Massachusetts General Hospital ("MGH") for the design of a Phase 2 clinical trial evaluating rinvatercept in patients with amyotrophic lateral sclerosis ("ALS") within the Healey ALS MyMatch program ("ALS MyMatch"), led by the Sean M. Healey & AMG Ce

    3/9/26 8:00:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference

    LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it presented additional data from its Phase 1 clinical trial of rinvatercept (KER-065) in healthy volunteers at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. "We are pleased to present additional data that further underscore the wide-ranging therapeutic potential

    3/9/26 8:00:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

    LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2025. "The previous year was an important period of transition for the Company, during which we sharpened our strategic priorities," said Jasbir S. Seehra, Ph.D., President and Chief Executive

    3/4/26 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Adar1 Capital Management, Llc bought $328,127 worth of shares (34,925 units at $9.40) (SEC Form 4)

    4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

    4/11/25 9:57:19 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bienaime Jean Jacques

    4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

    4/17/26 4:15:09 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Seehra Jasbir

    4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

    4/6/26 4:15:08 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Cho Esther

    4/A - Keros Therapeutics, Inc. (0001664710) (Issuer)

    3/27/26 4:15:14 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    SEC Filings

    View All

    SEC Form DEFA14A filed by Keros Therapeutics Inc.

    DEFA14A - Keros Therapeutics, Inc. (0001664710) (Filer)

    4/22/26 4:03:57 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Keros Therapeutics Inc.

    DEF 14A - Keros Therapeutics, Inc. (0001664710) (Filer)

    4/22/26 4:01:20 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Keros Therapeutics Inc.

    144 - Keros Therapeutics, Inc. (0001664710) (Subject)

    3/31/26 9:57:38 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Financials

    Live finance-specific insights

    View All

    Keros Therapeutics Reports Third Quarter 2025 Financial Results

    LEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended September 30, 2025. "We are excited that our partner Takeda plans to advance elritercept into a Phase 3 clinical trial to evaluate elritercept in the first-line setting in myelodysplastic syndromes," said Jasbir S. Seehra, Ph.D., President and Chief Executiv

    11/5/25 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

    AUSTIN, Texas, Aug. 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "we"), the largest stockholder of Keros Therapeutics (NASDAQ:KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released an open letter to Keros' Board of Directors (the "Board") expressing its disappointment with the Board's refusal to engage with ADAR1 on the Company's strategy, capital allocation priorities and Board refreshment. The full text of the letter is below. Dear Members of the Board: In July, we wrote to the Board privately to propose an in-person meeting to discuss our ideas to maximize stockholder value. We had

    8/21/25 8:30:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros to Exclusively Prioritize the Clinical Advancement of KER-065

    Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced a strategic realignment designed to reallocate resources towards the development of its key clinical program, KER-065. As part of thi

    8/6/25 4:15:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Leadership Updates

    Live Leadership Updates

    View All

    Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

    LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2025. "The previous year was an important period of transition for the Company, during which we sharpened our strategic priorities," said Jasbir S. Seehra, Ph.D., President and Chief Executive

    3/4/26 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Appoints Charles Newton to its Board of Directors

    LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Charles Newton to its Board of Directors, effective March 9, 2026. "We are pleased to welcome Mr. Newton to Keros' Board of Directors," said Jean-Jacques Bienaimé, Chair of the Board of Directors. "His extensive expertise in healthcare finance and capital markets, coupled with

    2/26/26 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

    LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Yung H. Chyung, M.D., as Keros' Chief Medical Officer, effective as of November 1, 2024. "We are thrilled to welcome Yung to Keros and look forward to leveraging his development and TGF-ß superfamily expertise as we continue to advance our clinical programs," said Chair and Chi

    10/16/24 8:00:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

    SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

    2/13/24 6:38:35 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

    SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

    2/9/24 9:16:07 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

    SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

    1/26/24 5:26:51 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care